|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
SundayTeva Subpoenaed in Marketing of Copaxone (Glatiramer Acetate)![]() Teva said the government is looking into possible violations of the federal False Claims Act and is seeking information dating back to the beginning of 2006. The company also said it is in the process of complying with the subpoena but didn't give further details in its filing with the U.S. Securities and Exchange Commission. Copaxone is Teva's top-selling drug and is expected to face generic competition this year. Last week, the company reported Copaxone's sales in the fourth quarter rose 8% to $1.14 billion, making up about 20% of its top line. The government investigation also looked at several other major drug companies. READ MORE |